Alnylam Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $1,167,175 | $1,097,033 | $1,249,026 | $773,689 |
Gross Profit | 956,053 | 829,310 | 1,051,795 | 630,736 |
EBITDA | 152,367 | 145,224 | 297,170 | 18,832 |
EBIT | 131,718 | 283,367 | 4,888 | |
Net Income | 205,991 | 186,419 | 251,084 | -66,277 |
Net Change In Cash | 1,167,175 | 1,097,033 | 1,249,026 | 773,689 |
Free Cash Flow | 48,671 | 140,263 | 312,967 | 139,437 |
Cash | 1,710,779 | 1,657,250 | 1,490,249 | 1,113,685 |
Basic Shares | 138,226 | 136,281 | 137,348 | 129,676 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $3,713,937 | $2,248,243 | $1,828,292 | $1,037,418 |
Gross Profit | 3,036,771 | 1,924,873 | 1,517,886 | 868,601 |
EBITDA | 557,236 | -178,847 | -258,242 | -926,557 |
EBIT | 501,578 | -235,517 | -312,296 | -971,025 |
Net Income | 313,747 | -278,157 | -440,242 | -1,131,156 |
Net Change In Cash | 3,713,937 | 2,248,243 | 1,828,292 | 1,037,418 |
Cost of Revenue | 53,833 | |||
Free Cash Flow | 465,383 | -42,589 | 41,945 | -613,333 |
Cash | 1,657,250 | 966,428 | 812,688 | 866,394 |
Basic Shares | 134,684 | 127,651 | 124,906 | 121,689 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $1.99 |
2025-12-31 | $1.25 |
2025-09-30 | $2.90 |
2025-06-30 | $0.32 |